Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects With Metastatic Melanoma

NCT04109456 is registered in ClinicalTrials.gov with InxMed (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT04109456
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04109456 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects With Metastatic Melanoma
Lead sponsor
InxMed (Shanghai) Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
March 16, 2020
Completion date
December 20, 2024
Enrollment
51 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma